Complement activation by PVA as measured by ELIFA (enzyme-linked immunoflow assay) for SC5b-9
Source abstract
Abstract
Polyvinyl alcohol (PVA) coated onto polyethylene (PE) tubes exposed to human serum for 1 hour at 37 degrees C resulted in the production of 1.03 +/- 0.04 microg/cm2 of the soluble form of the terminal membrane attack complex, SC5b-9. This was approximately 20 x that produced by the polyethylene. About one quarter of this total was found associated with the surface of PVA. SC5b-9 concentrations were determined by enzyme-linked immunoflow assay (ELIFA) a variant on ELISA that involved drawing the test sample, the antibodies and the chromogenic reagent through a nitrocellulose membrane filter. ELIFA enabled analysis of protein concentrations in the presence of SDS, so that SDS (0.05%) was used to desorb adsorbed SC5b-9 prior to analysis together with SC5b-9 in the bulk to get a more complete picture of PVA-associated complement activation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Complement system in diseases · Platelet Disorders and Treatments · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (21)
Show source-provided references
1. ISO Standard 10993-4. In: AAMI standards and recommended practice, vol. 4, Biological evaluation of medical devices, 1995; p. 45–68.
2. Methods for assessing complement activation in the clinical immunology laboratory10.1016/0022-1759(93)90063-D ↗
3. Complement activation as index of haemodialysis membrane biocompatibility
4. Complement
5. Complement activation during hemodialysis10.1177/088532828900400202 ↗
6. The complement system and inflammation
7. Membrane proteins that protect against complement lysis10.1007/BF01837366 ↗
8. Complement: chemistry and pathways
9. Material induced up-regulation of leukocyte CD 11b during whole blood contact10.1002/(SICI)1097-4636(199609)32:1<29::AID-JBM4>3.0.CO;2-R ↗
10. A flow cytometric study of in vitro neutrophil activation by biomaterials10.1002/(SICI)1097-4636(19990305)44:3<289::AID-JBM7>3.0.CO;2-O ↗
11. Using ELISA to evaluate complement activation by reference biomaterials10.1007/BF00120343 ↗
12. Effect of heparin-PVA hydrogel on platelets in a chronic canine arterio-venous shunt10.1002/jbm.820230404 ↗
13. Platelet activation in whole blood by artificial surfaces
14. Black J. Material-induced complement activation: a new method of analysis. MASc thesis, University of Toronto, 1996.
15. Role of proteinase/antiproteinase inhibitor disequilibrium in the bioincompatibility induced by artificial surfaces
16. Complement activation during hemodialysis10.1111/j.1525-1594.1984.tb04291.x ↗
17. Anaphylatoxin formation during hemodialysis10.1038/ki.1983.226 ↗
18. Complement activation produced by biomaterials
19. Analysis of the complement C3 fragments associated with hemodialysis membranes10.1038/ki.1989.26 ↗
20. Fluid phase generation of the terminal complement complex as a novel index of bioincompatibility10.1038/ki.1990.36 ↗
21. Plasma protein adsorption to hemodialysis membranes10.1002/jbm.820270406 ↗